The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) with paclitaxel plus ramucirumab (PTX-RAM) switch maintenance versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: A secondary endpoint of the ARMANI phase 3 randomized trial.
 
Eleonora Cristarella
No Relationships to Disclose
 
Giovanni Randon
Honoraria - Accademia Nazionale Di Medicina (ACCMED)
 
Sabina Murgioni
No Relationships to Disclose
 
Ferdinando De Vita
No Relationships to Disclose
 
Samantha Di Donato
No Relationships to Disclose
 
Elisa Giommoni
No Relationships to Disclose
 
Andrea Spallanzani
Honoraria - Astellas Amgen BioPharama; AstraZeneca; Daiichi Sankyo; Jazz Pharmaceuticals; MSD
 
Alessandro Bittoni
No Relationships to Disclose
 
Claudio Chini
No Relationships to Disclose
 
Antonia Strippoli
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex (Inst)
 
Tiziana Latiano
No Relationships to Disclose
 
Oronzo Brunetti
Consulting or Advisory Role - kyowa kirin
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; Mylan
 
Stefano Tamberi
Consulting or Advisory Role - AstraZeneca; Seagen; Takeda
Speakers' Bureau - AstraZeneca
 
Giovanni Cardellino
No Relationships to Disclose
 
Daniele Spada
No Relationships to Disclose
 
Lorenzo Fornaro
Honoraria - BMS GmbH & Co. KG; Incyte; Lilly; MSD; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Daiichi Sankyo; BeiGene; Incyte; Lilly; MSD; SERVIER; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BMS GmbH & Co. KG (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Incyte (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche (Inst)
 
Sara Alessandrini
No Relationships to Disclose
 
Massimo Di Maio
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Eisai; Ipsen; Janssen; MSD Oncology; Novartis; Pfizer; Roche; Takeda; Viatris
Consulting or Advisory Role - AstraZeneca; Eisai; Ipsen; Janssen; MSD Oncology; Novartis; Pfizer; Roche; Takeda; Viatris
Research Funding - GlaxoSmithKline (Inst)
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Margherita Ambrosini
No Relationships to Disclose